Inactive Instrument

Clinigen Group plc

Equities

CLIN

GB00B89J2419

CLINIGEN : NOTIFICATION OF FULL YEAR RESULTS

August 28, 2020 at 08:09 am EDT

Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2020 on Thursday 17 September 2020.

The analyst meeting will be held virtually at 9.30am. Analysts should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register their interest.

Contact:

Shaun Chilton

Tel: +44 (0) 1283 495 010

Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

Latest news about Clinigen Group plc

Clinigen Launches NaviGATE an Educational Programme for Rare Disease Patients and Organizations	23-09-12	CI
CNX Therapeutics Limited acquired Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol®, four cancer support therapies from Clinigen Limited.	23-08-09	CI
Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2022	23-05-08	CI
Adragos Pharma GmbH completed the acquisition of Lamda Laboratories S.A. from Clinigen Limited.	23-04-02	CI
Adragos Pharma GmbH signed a definitive agreement to acquire Lamda Laboratories S.A. from Clinigen Limited.	23-03-19	CI
Iovance Biotherapeutics, Inc. entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited for approximately £210 million.	23-01-22	CI
Clinigen Group plc acquired Drug Safety Navigator, LLC.	22-12-30	CI
Clinigen Notes Results from the MIROCALS Trial Investigating Low Dose Proleukin® (Aldesleukin) in Patients with Amyotrophic Lateral Sclerosis	22-12-08	CI
Clinigen Group plc agreed to acquire Drug Safety Navigator, LLC.	22-11-28	CI
Clinigen Expands US Site Capacity in Response to Growing Demand for Clinical Supplies Management Services	22-05-24	CI
Triton Funds Company Completes Takeover Of Clinigen	22-04-04	MT
Triton Fund V SCSP, Triton Fund V L.P., Triton Fund V F&F No. 5 SCSp, Triton Fund V F&F No.3 L.P., Triton Fund V F&F L.P., Triton Fund V F&F No. 2 L.P., Triton Fund V F&F 4 SCSp and Triton C Investment A L.P., managed by Triton completed the acquisition of Clinigen Group plc.	22-04-03	CI
UK's High Court Approves Clinigen's Takeover	22-03-31	MT
Clinigen's Fiscal H1 Profit Sinks As Sales, Administrative Costs Rise	22-02-23	MT
Clinigen Group plc Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-23	CI
Scentre Group CEO/Managing Director to Step Down End-September; Shares Fall 5%	22-02-22	MT
Scentre Signals Higher Distribution, Faster Earnings Growth in Fiscal Year 2022	22-02-22	DJ
Clinigen Expects to Complete $1.8 Billion Sale to Triton in Early April	22-02-16	MT
Clinigen Group plc Signs Distribution Agreement with Deciphera Pharmaceuticals	22-02-09	CI
Clinigen Group Declares the Voting Results	22-02-08	CI
Clinigen Group plc Issues Open Letter to the Shareholders	22-01-20	CI
Clinigen Postpones Court, General Meetings following Increased Takeover Offer	22-01-18	MT
Global markets live: Credit Suisse, Unilever, Pfizer, Volkswagen, Triton...	22-01-17
UK's Clinigen agrees to sweetened $1.8 billion Triton take-private deal	22-01-17	RE
Clinigen Receives Sweetened $1.8 Billion Takeover Bid From Triton	22-01-17	MT

Chart Clinigen Group plc

Duration

Period

More charts

Company Profile

Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.

Sector

More about the company